EarningsQ2 2026 Earnings Report
CH:BSFA Q2 2026 EPS Results
Actual EPSCHF1.84
Consensus EPSCHF1.70
Beat/MissBeat by +CHF0.14
One Year Ago EPSCHF1.49
CH:BSFA Q2 2026 Revenue Results
Actual RevenueCHF220.92M
Expected RevenueCHF216.01M
Beat/MissBeat by +CHF4.91M
YoY Revenue Growth+25.87%
Earnings Announcement Details
QuarterQ2 2026
Date08/07/2026
TimeBefore Open
Conference CallFriday, August 7, 2026
CH:BSFA Upcoming Earnings
ANI Pharmaceuticals's next earnings date is estimated for November 11, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
CH:BSFA Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call highlighted strong operational execution with record Q2 revenue, record adjusted EBITDA, robust Cortrophin momentum, a major sales force expansion, continued generics execution and a healthy balance sheet. Near-term headwinds include timing-related adjustments (modest Cortrophin guidance revision), higher cost of sales and increased SG&A from the gout expansion, and a Q3 EBITDA sequential dip tied to milestone timing and fully loaded expansion costs. Management emphasizes continued confidence in multi-year Cortrophin growth and reaffirmed full-year company guidance, indicating that the positives (growth, margin expansion outlook, cash generation and strategic progress) meaningfully outweigh the short-term operational and timing challenges.Company Guidance
Record Quarterly Revenue
Total net revenues of $266.0 million in Q2 2026, representing 26% year-over-year growth and a sequential acceleration vs Q1.
Cortrophin Gel Momentum and Record Sales
Cortrophin Gel net revenues of $117.1 million in Q2 2026, up 43% year-over-year and 56% versus Q1 2026; company expects Cortrophin full-year revenue of $520 million to $540 million (50%–55% growth vs 2025).
Record Adjusted EBITDA and EPS Improvement
Adjusted non-GAAP EBITDA reached a record $71.6 million in Q2, up 32% year-over-year; adjusted non-GAAP diluted EPS was $2.21 versus $1.80 in the prior year period (≈23% increase).
Generics Execution and Pipeline
Generics revenue of $99.1 million in Q2, up 10% year-over-year; 12 generics launched in 2026 to date with at least 15 expected for the full year; company remains the #2 filer in overall Paragraph IV/CGT filings.
Major Sales Force Expansion
Completed the largest rare disease commercial expansion in company history, increasing the sales force by 50% to approximately 180 representatives to support Cortrophin (including a dedicated gout-focused team).
Healthy Balance Sheet and Cash Generation
Unrestricted cash of $360.2 million at quarter end (up $74.6 million vs Dec 31, 2025); cash flow from operations $56.7 million in Q2 and $115 million year-to-date; trailing 12-month adjusted EBITDA of $259.6 million with net leverage ~1.0x and gross leverage 2.4x.
Strategic Licensing Contribution
Recognized $17.7 million in Q2 related to the Harmony Biosciences licensing transaction (including $9.7 million of royalties and $8.0 million of milestone-related revenue), with an additional $2.0 million expected in Q3.
Reaffirmed Full-Year Guidance
Reaffirmed 2026 company guidance: total net revenue of $1.08B–$1.14B (~26% growth), adjusted non-GAAP EBITDA of $285M–$300M (~27% growth), and adjusted non-GAAP EPS of $9.19–$9.69; ILUVIEN revenue guidance reaffirmed at $78M–$83M.
Clinical and Commercial Progress for ILUVIEN
ILUVIEN revenue of $18.7 million in Q2; top-line Phase IV SYNCHRONICITY results for NIU-PS announced with detailed data to be presented at a medical meeting in Q4 2026, supporting future engagement with retina specialists.
CH:BSFA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed